Navigation Links
Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
Date:9/6/2011

00.89&rank=1">http://clinicaltrials.gov/ct2/show/NCT01325428?term=afatinib+1200.89&rank=1.  U.S. investigators who are interested in becoming involved in this study and have potentially eligible patients should contact Boehringer Ingelheim at: clintriage.rdg@boehringer-ingelheim.com.  

About Afatinib

Afatinib is an investigational compound.  Afatinib is not approved by the FDA; its safety and efficacy have not been established.  

Afatinib is an orally-administered irreversible inhibitor of the erbB family of receptor tyrosine kinases, specifically EGFR and HER2.  In addition to breast cancer, afatinib is also in late-stage clinical development in NSCLC, the most common type of lung cancer. LUX-Lung 3 is a phase III study in patients with NSCLC and EGFR mutations, which compares single-agent afatinib with chemotherapy using cisplatin/pemetrexed as first-line treatment.

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments. This commitment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need, including seven investigational compounds in different phases of development for solid tumors and hematological cancers.

The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition.  Afatinib is currently in phase III clinic
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DARTâ„¢-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ... size less than 10 bps, yet are surprisingly capable ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ... insulin delivery systems especially for type 1 ...
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire/ ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ... OBJECTIVES A drug delivery ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... End Prostate Cancer to Take Strides for the Cause WASHINGTON, ... country and runners are hitting the pavement to ramp up ... The Project to End Prostate Cancer has joined forces with ... Marathon to build upon its Team ZERO endurance program and ...
... US Farms, Inc. (OTC Bulletin Board: USFM), announces the launch ... which will operate as a division of US Farms, Inc. ... or wholesales for $89.95 per case (12 bottles). US Farms ... Card, Discover, or American Express.US Farms Aloe Vera Juice is ...
... finds , , THURSDAY, April 9 (HealthDay News) -- More than ... have elevated levels of the residue of secondhand smoke in ... suggests that nonsmokers in the city -- a number the ... protected from cigarette smoke, it says. , "This is not ...
... Nursing InitiativeWASHINGTON, April 9 To provide compassionate, highly-trained ... nation,s Veterans, the Department of Veterans Affairs (VA) is ... nursing schools. With these new partnerships, the VA ... the department and nursing schools from 10 to 15."The ...
... Begin in Southern California SALT LAKE CITY, April ... nursing schools were turned away, despite a nationwide shortage ... healthcare, Western Governors University , www.wgu.edu ... well as healthcare institutions to develop the first national, ...
... streamlines voice and data management NASHVILLE, Tenn., April ... TWTC ), a leading provider of managed ... today announced the successful installation of data and ... services provided by tw telecom for ...
Cached Medicine News:Health News:Team ZERO to Run to End Prostate Cancer in 2009 Marathons 2Health News:US Farms, Inc. Launches Aloe Vera Juice Web Site 2Health News:US Farms, Inc. Launches Aloe Vera Juice Web Site 3Health News:Secondhand Smoke Affecting Millions of New Yorkers 2Health News:VA Announces New Nursing Academy Sites 2Health News:Western Governors University to Launch Nation's First Competency-Based B.S. in Nursing Leading to RN Licensure 2Health News:Western Governors University to Launch Nation's First Competency-Based B.S. in Nursing Leading to RN Licensure 3Health News:Metropolitan Nashville Hospital Authority Completes Voice and Data Upgrade with tw telecom's Network Solutions 2Health News:Metropolitan Nashville Hospital Authority Completes Voice and Data Upgrade with tw telecom's Network Solutions 3Health News:Metropolitan Nashville Hospital Authority Completes Voice and Data Upgrade with tw telecom's Network Solutions 4
The STAAR ELASTIMIDE™ lens, combines the best of foldable lens technology with traditional design. This lens contains a cast-molded, silicone optic with modified Polyimide haptics....
Foldable Silicone Multi-piece Lens....
... The PhacoFlexII SI30NB is foldable ... to it's patients. It is ... The SI30NB is indicated for ... correction of aphakia in adults ...
Liberty Three Piece PMMA Lens with UV Absorber....
Medicine Products: